{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T12:40:20Z","timestamp":1716640820729},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00406-024-01810-2","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:02:09Z","timestamp":1712901729000},"page":"755-757","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beneficial and adverse effects of ketamine and its enantiomers, and the underlying mechanisms of ECT and rTMS efficacy"],"prefix":"10.1007","volume":"274","author":[{"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"1810_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01716-5","author":"P Riera-Serra","year":"2023","unstructured":"Riera-Serra P, Navarra-Ventura G, Castro A, Gili M, Salazar-Cedillo A, Ricci-Cabello I, Rold\u00e1n-Esp\u00ednola L, Coronado-Simsic V, Garc\u00eda-Toro M, G\u00f3mez-Juanes R, Roca M (2023) Clinical predictors of suicidal ideation, suicide attempts and suicide death in depressive disorder: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01716-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1810_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01675-x","author":"P Phalen","year":"2023","unstructured":"Phalen P, Kimhy D, Jobes D, Bennett M (2023) Emotional distress and dysregulation as treatment targets to reduce suicide in psychosis: a scoping review. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01675-x","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"7","key":"1810_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00406-023-01570-5","volume":"273","author":"K Hashimoto","year":"2023","unstructured":"Hashimoto K (2023) Arketamine for cognitive impairment in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 273(7):1513\u20131525. https:\/\/doi.org\/10.1007\/s00406-023-01570-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1810_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-024-01770-7","author":"K Hashimoto","year":"2024","unstructured":"Hashimoto K (2024) Are, \u201cmystical experiences\u201d essential for antidepressant actions of ketamine and the classic psychedelics? Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-024-01770-7","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1810_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01735-2","author":"MH Chen","year":"2023","unstructured":"Chen MH, Su TP, Li CT, Lin WC, Wu HJ, Tsai SJ, Bai YM, Mao WC, Tu PC (2023) Effects of melancholic features on positive and negative suicidal ideation in patients with treatment-resistant depression and strong suicidal ideation receiving low-dose ketamine infusion. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01735-2","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1810_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01732-5","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Du Z, Shen Y, Zhou Q, Zhu H (2023) The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01732-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1810_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01611-z","author":"S Chen","year":"2023","unstructured":"Chen S, Yang JJ, Zhang Y, Lei L, Qiu D, Lv HM, Sun ZT, Hashimoto K, Yang JJ (2023) Risk of esketamine anesthesia on the emergence delirium in preschool children after minor surgery: a prospective observational clinical study. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01611-z","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1810_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01708-5","author":"S Stuiver","year":"2023","unstructured":"Stuiver S, Pottk\u00e4mper JCM, Verdijk JPAJ, Ten Doesschate F, Aalbregt E, van Putten MJAM, Hofmeijer J, van Waarde JA (2023) Cortical excitation\/inhibition ratios in patients with major depression treated with electroconvulsive therapy: an EEG analysis. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01708-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"7","key":"1810_CR9","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00406-023-01637-3","volume":"273","author":"GR Wu","year":"2023","unstructured":"Wu GR, Baeken C (2023) Precision targeting in prediction for rTMS clinical outcome in depression: what about sgACC lateralization, metabolic connectivity, and the potential role of the cerebellum? Eur Arch Psychiatry Clin Neurosci 273(7):1443\u20131450. https:\/\/doi.org\/10.1007\/s00406-023-01637-3","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1810_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01704-9","author":"ME Boylu","year":"2023","unstructured":"Boylu ME, Turan \u015e, G\u00fcler EM, Boylu FB, K\u0131l\u0131\u00e7 \u00d6, Ko\u00e7yi\u011fit A, K\u0131rp\u0131nar \u0130 (2023) Changes in neuroactive steroids, neurotrophins and immunological biomarkers after monotherapy 8-week rTMS treatment and their relationship with neurocognitive functions in depression. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01704-9","journal-title":"Eur Arch Psychiatry Clin Neurosci"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01810-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-024-01810-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01810-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T12:10:24Z","timestamp":1716639024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-024-01810-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1007\/s00406-024-01810-2","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"12 April 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Hashimoto is the inventor of filed patent applications on \u201cThe use of <i>R<\/i>-ketamine in the treatment of psychiatric diseases\u201d, \u201c(<i>S<\/i>)-norketamine and salt thereof as pharmaceutical\u201d, \u201c<i>R<\/i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder\u201d, \u201cPreventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases\u201d, \u201c<i>R<\/i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder\u201d, and \u201cTGF-\u03b21 in the treatment of depression\u201d by the Chiba University. Dr. Hashimoto has also received speakers\u2019 honoraria, consultant fee, or research support from Abbott, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. Dr. Hashimoto is Editor at European Archives of Psychiatry and Clinical Neuroscience.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}